NEW PUBLICATIONS

JANUARY 2025

Drug-drug interactions
Clin Pharmacol Ther. 2025;117:523-533. Effects of cimetidine and dolutegravir on the endogenous drug-drug interaction biomarkers for organic cation transporter 2 and multidrug and toxin extrusion protein 1 in healthy volunteers. Koishikawa T, Fujiwara K, Taskar K, Zamek-Gliszczynski MJ, Yoshida K, Chu X, Hirabayashi H, Mao J, Rockich K, Takashima T, Yamaura Y, Lai Y, Tomoda Y, Kito T, Maeda K, Furihata K, Sugiyama Y, Kusuhara H. PubMed
https://pubmed.ncbi.nlm.nih.gov/39497599/

bioRxiv [Preprint]. 2024;In press. Quantitative contributions of hepatic and renal organic cation transporters to the clinical pharmacokinetic cimetidine-metformin interaction. Ailabouni AS, Singh DK, Thakur A, Paine MF, Boone EC, Gaedigk A, Prasad B. PubMed
https://pubmed.ncbi.nlm.nih.gov/39605472/

Gastrointestinal transporters in Chinese volunteers
Clin Pharmacol Ther. 2024;In press. Distribution characteristics and impacting factors of drug CYP enzymes and transporters in the gastrointestinal tract of chinese healthy subjects. Zhang M, Zhang L, Suo B, Wei Y, Xu Y, Jiang M, Dong J, Li X, Song Z, Liu D. PubMed
https://pubmed.ncbi.nlm.nih.gov/39582241/

Cancer multidrug resistance
Eur J Pharmacol. 2025;In press. Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2. Li YC, Lin BH, Murakami M, Wu YS, Hung TH, Chen CC, Ambudkar SV, Wu CP. PubMed
https://pubmed.ncbi.nlm.nih.gov/39725134/

Cancers (Basel). 2024;16:3904. The emerging role of long noncoding RNAs in sorafenib resistance within hepatocellular carcinoma. Vij P, Hussain MS, Satapathy SK, Cobos E, Tripathi MK. PubMed
https://pubmed.ncbi.nlm.nih.gov/39682093/

Transporter inhibition and toxicity
Clin Pharmacol Ther. 2024;In press. Inhibition of OATP1B1/3 rather than UGT1A1 may be the major cause of the bilirubin elevation after atazanavir administration. Dong J, Sharma P, Emara R, Cheung D, Tang W, Zhou D, Boulton DW, Någård M, Park MS. PubMed
https://pubmed.ncbi.nlm.nih.gov/39673699/

Expert Opinion Drug Metab Toxicol. 2025;In press. Human liver cell-based assays for the prediction of hepatic bile acid efflux transporter inhibition by drugs. Fardel O, Moreau A, Jouan E, Denizot C, Le Vée M, Parmentier Y. PubMed
https://pubmed.ncbi.nlm.nih.gov/39799554/

Toxicol Mech Methods. 2025;In press. Brij 35 inhibited the CYP2E1-mediated metabolism and P-gp mediated transport of paracetamol in rats and in vitro models: Amelioration of paracetamol toxicity. Chunduru N, Pingili RB, Dirisala VR, K, Prasad.PubMed
https://pubmed.ncbi.nlm.nih.gov/39838705/

BSEP regulation
PLoS One. 2024;19:e0315243. Interleukin 1β suppresses bile acid-induced BSEP expression via a CXCR2-dependent feedback mechanism. Angendohr C, Missing L, Ehlting C, Wolf SD, Lang KS, Vucur M, Luedde T, Bode JG. PubMed
https://pubmed.ncbi.nlm.nih.gov/39680527/

Altered hepatocyte hopping
Acta Pharm Sin B. 2024;14:4874-4882. Nonalcoholic steatohepatitis increases plasma retention of sorafenib-glucuronide in a mouse model by altering hepatocyte hopping. Toth E, Li H, Frost K, Sample P, Jilek J, Greenfield S, You D, Kozlosky D, Goedken M, Paine MF, Aleksunes L, Cherrington N. PubMed
https://pubmed.ncbi.nlm.nih.gov/39664440/